| Autor: |
Razelle Kurzrock, Andrew Sharabi, Donald A. Barkauskas, Vighnesh Walavalkar, Aaron Goodman, Shumei Kato |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.22468280.v1 |
| Popis: |
Supplemental Table 1. Patient characteristics of all six individuals with MDM2/4 amplifications who received immunotherapy. Supplemental Table 2. Patient characteristics among patients who received anti-PD-1/PD-L1 (N = 102) Supplemental Table 3. Patients with EGFR alterations and TTF less than 2 months on immunotherapy (N=8 of a total of 10 patients with EGFR alterations). Supplemental Table 4. Patients with DNM3TA alterations and TTF less than 2 months on immunotherapy (N=4 of a total of 5 patients with DNM3TA alterations). Supplemental Figure 1. Evaluation of tumor biopsy at the time of progression (Case #4). Supplemental Figure 2.A. Case #11 Supplemental Figure 2.B. Case #13 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
